Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1999 1
2000 2
2001 2
2002 2
2003 1
2004 2
2005 1
2006 6
2007 1
2008 2
2009 4
2010 6
2011 12
2012 8
2013 11
2014 9
2015 16
2016 11
2017 15
2018 14
2019 20
2020 19
2021 24
2022 19
2023 7
2024 14
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.
Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, Kloth C, Stamopoulou A, Moritz T, Lode HN, Siebert N, Blasczyk R, Goudeva L, Schambach A, Köhl U, Eiz-Vesper B, Esser R. Glienke W, et al. Among authors: rossig c. Front Immunol. 2022 Mar 24;13:839783. doi: 10.3389/fimmu.2022.839783. eCollection 2022. Front Immunol. 2022. PMID: 35401506 Free PMC article.
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.
Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, Bourquin JP, Handgretinger R, Brethon B, Rössig C, Kormany WN, Viswagnachar P, Chen-Santel C. Locatelli F, et al. Among authors: rossig c. Blood Adv. 2022 Feb 8;6(3):1004-1014. doi: 10.1182/bloodadvances.2021005579. Blood Adv. 2022. PMID: 34979020 Free PMC article.
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Díaz-de-Heredia C, Bielorai B, Rossig C, van der Velden VHJ, Ammerlaan ACJ, Thano A, van der Sluis IM, den Boer ML, Chen Y, Sleight B, Brethon B, Nysom K, Sramkova L, Øra I, Vinti L, Chen-Santel C, Zwaan CM. Brivio E, et al. Among authors: rossig c. Blood. 2021 Mar 25;137(12):1582-1590. doi: 10.1182/blood.2020007848. Blood. 2021. PMID: 33067614 Free PMC article. Clinical Trial.
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM. Pennesi E, et al. Among authors: rossig c. Leukemia. 2022 Jun;36(6):1516-1524. doi: 10.1038/s41375-022-01576-3. Epub 2022 Apr 25. Leukemia. 2022. PMID: 35468945 Free PMC article. Clinical Trial.
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.
Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puyó P, Micalizzi C, Rossig C, Shukla N, Gilad G, Locatelli F, Baruchel A, Zwaan CM, Bezler NS, Rubio-San-Simón A, Taussig DC, Raetz EA, Mao ZJ, Wood BL, Alvarez Arias D, Krevvata M, Nnane I, Bandyopadhyay N, Lopez Solano L, Dennis RM, Carson R, Vora A. Bhatla T, et al. Among authors: rossig c. Blood. 2024 Nov 21;144(21):2237-2247. doi: 10.1182/blood.2024024493. Blood. 2024. PMID: 39158071 Clinical Trial.
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, Koenecke C, Bakhtiar S, Künkele A, Meisel R, Müller F, Müller I, Penack O, Rettinger E, Sauer MG, Schlegel PG, Soerensen J, von Stackelberg A, Strahm B, Hauer J, Feuchtinger T, Jarisch A. Bader P, et al. Among authors: rossig c. Blood Adv. 2023 Jun 13;7(11):2436-2448. doi: 10.1182/bloodadvances.2022008981. Blood Adv. 2023. PMID: 36607834 Free PMC article.
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Fischer-Riepe L, et al. Among authors: rossig c. Clin Cancer Res. 2024 Aug 15;30(16):3564-3577. doi: 10.1158/1078-0432.CCR-23-3157. Clin Cancer Res. 2024. PMID: 38593230
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial.
Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, Sleight B, Locatelli F, Brethon B, Rossig C, Engstler G, Nilsson A, Bruno B, Petit A, Bielorai B, Rizzari C, Rialland F, Rubio-San-Simón A, Sirvent FJB, Diaz-de-Heredia C, Rives S, Zwaan CM. Pennesi E, et al. Among authors: rossig c. Haematologica. 2024 Oct 1;109(10):3157-3166. doi: 10.3324/haematol.2023.284409. Haematologica. 2024. PMID: 38186333 Free PMC article. Clinical Trial.
200 results